ici 204,219 has been researched along with pancuronium in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Arita-Morioka, K; Mizunoe, Y; Ogura, T; Sugimoto, S; Yamanaka, K | 1 |
1 review(s) available for ici 204,219 and pancuronium
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for ici 204,219 and pancuronium
| Article | Year |
|---|---|
Novel strategy for biofilm inhibition by using small molecules targeting molecular chaperone DnaK.
Topics: Benzimidazoles; Benzoates; Biofilms; Dose-Response Relationship, Drug; Escherichia coli; Escherichia coli Proteins; Flavonoids; HSP70 Heat-Shock Proteins; Indoles; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Molecular Chaperones; Molecular Targeted Therapy; Pancuronium; Phenylcarbamates; Staphylococcus aureus; Sulfonamides; Telmisartan; Tosyl Compounds; Vancomycin | 2015 |